共查询到20条相似文献,搜索用时 671 毫秒
1.
诺维本持续静脉输注联合顺铂治疗转移性乳腺癌临床观察 总被引:2,自引:0,他引:2
目的 探索诺维本不同用药方法联合顺铂治疗转移性乳腺癌的疗效和不良反应。方法 对67例转移性乳腺癌采用随机分组,其中42例予诺维本持续静脉输注联合顺铂(A组),25例予诺维本常规静脉冲入联合顺铂(B组)。结果 A组有效率(CR+PR)47.62%。B组有效率(CR+PR)40.0%,毒副反应A组明显低于B组。结论 诺维本持续静脉输注较常规静脉冲入联合顺铂治疗转移性乳腺癌疗效有所提高,毒副反应明显减轻。 相似文献
2.
应用ACNU与Me—CCNU联合化疗治疗进展期胃癌的随机研究 总被引:2,自引:0,他引:2
作者比较了亚硝酸脲类药物盐酸嘧啶亚硝脲(ACNU)和甲环亚硝脲(Me-CCNU)联合化疗对进展期胃癌的疗效。103例进展期胃癌分为A组(Me-CCNU,5-Fu和ADM)和B组(ACNU,5-Fu和ADM)进行随机研究,结果,A组无CR和PR者,B组无CR,但PR者8/46(17.4%),B组有效率为17.4%,A组有疗效为0%,中位生存期B组为112天,A组为108天,在疗程中,两组均未发生严重 相似文献
3.
用PCMF和CAF方案治疗晚期乳腺癌的临床观察 总被引:5,自引:0,他引:5
对45例Ⅳ期乳腺癌采用PCMF或CAF方案姑息性化疗的近期疗效、毒副反应等作了比较总结,分析两种方案的利弊及临床适用价值。45例中,PCMF组22例,CR2例(9.1%)、PR8例,有效率(CR+PR)45.5%;CAF组23例,CR2例(8.7%)、PR8例,有效率43.5%;两组疗效相当,(P〉0.05),其结果与国外文献报道相近。PCMF组的心脏毒性、脱发发生率低于CAF组(P〈0.05). 相似文献
4.
我院从1994年到1995年12月,用PCMF和CAF联合化职方案治疗晚期乳腺癌48例,效果满意,PCMF方案的有效率为66.7%(16/24),其中CR为29.2%(7/24),PR为37.5%(9/24),CAF方案的有效率为58.3%(14/24),其中CR为20.8%(5/24),PR主37.5%(9/24),两种方案疗效无显著差别(P〉0.05)。中位缓解期分别为7和8个月,两种方案相近 相似文献
5.
6.
7.
HDCF/5-Fu、DDP联合方案治疗晚期鼻咽癌的近期疗效分析 总被引:1,自引:0,他引:1
为了提高5-Fu+DDP方案治疗复发、转移性鼻咽癌的临床疗效,对28例晚期NPC患者给予2个以上疗程的HDCF/5-Fu+DDP方案化疗,结果CR2例、PR11例、MR6例、SD4例、PD5例,总有效率为(CR+PR)46.4%,中位缓解期5.4个月(2~16个月)。毒性反应主要有WBC下降、恶心呕吐、口腔粘膜溃烂等。HDCF/5-Fu+DDP方案较传统的单用5-Fu+DDP方案疗效有明显提高,但毒性反应亦较重 相似文献
8.
乳腺癌c—erbB—2,表皮生长因子受体基因蛋白表达与预后的关系 总被引:2,自引:0,他引:2
以免疫组化ABC法检测乳腺癌c-erbB-2、表皮生长因子受体基因蛋白表达,研究其与预后的关系,结果:c-erbB-2、EGFR阳性表达率各为38.5%(25/65)和43.1%(28/65)。除EGFR表达与ER、PR负相关外,c-erbB-2,EGFR表达与临床预后因素无相关性,二者之间亦无相关性。c-erbB-2或EGFR阳性组术后生存显著差于阴性组(P〈0.01);多因素分析二者是显著影响 相似文献
9.
目的:探讨曲妥珠单抗(赫赛汀)联合吉西他滨(GEM)治疗表皮生长因子受体2(HER2)阳性的转移性乳腺癌(MBC)的疗效和不良反应。方法:HER2阳性的MBC女性患者9例,给予GEM1000mg/m2,静脉滴注,d1、d8、d15,4周重复;赫赛汀静脉滴注,首次4mg/kg,其后每周1次,2mg/kg,连续使用。结果:9例患者中,CR1例(11.1%),PR6例(66.7%),SD和PD各1例(11.1%),有效率(RR)为77.8%,疾病控制率(DCR)为88.9%;中位肿瘤进展时间(TTP)为18个月,中位总生存时间(OS)为23个月。主要毒性反应是骨髓抑制和消化道反应,且均为Ⅰ ~Ⅱ度。结论:赫赛汀联合吉西他滨对于难治性转移性乳腺癌是有效且安全的治疗方案。 相似文献
10.
目的 观察吉西他滨联合顺铂方案治疗ER、PR、HER-2均阴性对蒽环类耐药的晚期转移性乳腺癌的疗效和安全性。方法 34例对蒽环或紫杉类耐药晚期转移性乳腺癌患者,经免疫组化证实ER、PR、HER-2均阴性,给予吉西他滨联合顺铂方案治疗,具体用药为:吉西他滨1000mg/m2静脉滴注,第1,8天;顺铂25mg/m2静脉滴注,第1~3天。21天为1周期,至少2个周期,2周期后评价疗效和毒副反应。结果 34例患者均可评价疗效,获完全缓解(CR)2例(5.9%),部分缓解(PR)12例(35.3%),稳定(SD)14例(41.2%),进展(PD)6例(17.6%),总有效率(CR+PR)为41.2%;中位疾病进展时间为5.2个月。主要不良反应包括骨髓抑制和胃肠道反应,无化疗相关死亡。结论 吉西他滨联合顺铂方案对蒽环类或紫杉类耐药的转移性三阴性乳腺癌有较好的近期疗效,不良反应可耐受,是有效的解救方案之一。 相似文献
11.
12.
Furue H 《Gan to kagaku ryoho. Cancer & chemotherapy》1999,26(5):589-596
Principles for the development of effective clinical combination chemotherapy has been recognized for many years, and many trials have been continue to be used in the design of more effective combinations. Drugs to be used in the combination chemotherapy regimen are as follows: 1) Only those drugs proven effective should be combined, 2) Each drugs have a different mechanism of action, 3) Each drug have a different spectrum of toxicities, 4) Each drugs should be administered at their adequate dose intensity and schedule. Optimally, all agents would be administered simultaneously, but they can be administered in alternating sequence. However, the available results have not provided definitive evidence for the development of adequate, effective combination chemotherapy. Prospective randomized comparisons will eventually elucidate the better regimens. Further studies are warranted. 相似文献
13.
14.
15.
16.
SummaryWe evaluated the combination of ofloxacin with piperacillin, gentamicin, vancomycin, rifampin, clindamycin, and metronidazole by the checkerboard agar dilution method against 165 isolates which included Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, Pseudomonas aeruginosa, Providencia stuartii, Acinetobacter, Staphylococcus aureus, Bacteroides fragilis, and Citrobacter perfringens. Synergy of piperacillin-ofloxacin was demonstrated for 50% and 40% respectively of E. cloacae and P. aeruginosa. Some ofloxacin and piperacillin-resistant isolates were susceptible with the combination. Ofloxacin-gentamicin was indifferent for aerobic gram-negative species. Ofloxacin and vancomycin or gentamicin was indifferent for S. aureus and E. faecalis, but rifampin-ofloxacin showed addition. Combination of ofloxacin and metronidazole or clindamycin or erythromycin was indifferent for aerobic and anaerobic species.Ofloxacin could be combined with piperacillin with benefit against P. aeruginosa, but combination with aminoglycosides is not of benefit. 相似文献
17.
Combination of levofolinate calcium and 5-fluorouracil 总被引:1,自引:0,他引:1
Sasaki T 《Gan to kagaku ryoho. Cancer & chemotherapy》2000,27(2):315-322
It has been determined that in the combination of Leucovorin (LV) and 5-fluorouracil (5-FU), LV potentiates the cytotoxic effect of 5-FU based on biochemical modulation. Many data suggest that LV/5-FU is a very effective combination, and most clinicians worldwide now regard it as the standard therapy for colorectal cancer. In Japan, clinical examinations of this combination using Levofolinate calcium (I-LV) have shown its effectiveness, and I-LV/5-FU for gastric and colorectal cancer was authorized by the Ministry of Public Welfare in Oct. 1999. 相似文献
18.
J E Byfield 《Journal of clinical oncology》1985,3(8):1155-1157
19.
20.